Aug. 2, 2016
Amgen and Advaxis, Inc. have announced a global agreement for the development and commercialization of Advaxis’ ADXS-NEO. It is a novel, preclinical investigational cancer immunotherapy treatment that is designed to activate the immune system of a patient to respond against the unique mutations, or neoepitopes, contained in and identified from the tumor of each individual patient. This collaboration brings together the development expertise of Amgen in immuno-oncology with the MINE™ (My Immunotherapy Neo-Epitopes) program of Advaxis, which is uniquely positioned for developing a customized approach to treat cancer.
Under the terms of the agreement, Amgen receives exclusive worldwide rights for developing and commercializing ADXS-NEO. Furthermore, Amgen will be fully responsible for funding commercial and clinical activities. On the other hand, Advaxis will lead the clinical development of ADXS-NEO through proof-of-concept, retain manufacturing responsibilities, and receive development, sales, and regulatory milestone payments.
Sean E. Harper, M.D., executive vice president of Research and Development at Amgen, said: “Amgen’s collaboration with Advaxis leverages and enhances our development and commercialization expertise in novel immuno-oncology treatments. We look forward to partnering with Advaxis to advance this highly targeted and patient-specific treatment option for patients.”
“Amgen is a pioneer in the science of using living cells to develop biologic medicines, making them an incredibly strong partner to develop and commercialize Advaxis’ MINE. With Amgen’s resources, worldwide reach and a culture that embraces science and innovation, we are positioned to accelerate the clinical development program for ADXS-NEO to improve the lives of those who suffer from cancer,” said Daniel J. O’Connor, president and chief executive officer at Advaxis.